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Abstract
We report here in adult rat viral vector mediate-gene knockdown in the primary sensory neurons and the associated cellular
and behavior consequences. Self-complementary adeno-associated virus serotype 5 (AAV5) was constructed to express
green fluorescent protein (GFP) and a small interfering RNA (siRNA) targeting mammalian target of rapamycin (mTOR). The
AAV vectors were injected via an intrathecal catheter. We observed profound GFP expression in lumbar DRG neurons
beginning at 2-week post-injection. Of those neurons, over 85% were large to medium-diameter and co-labeled with NF200,
a marker for myelinated fibers. Western blotting of mTOR revealed an 80% reduction in the lumbar DRGs (L4–L6) of rats
treated with the active siRNA vectors compared to the control siRNA vector. Gene knockdown became apparent as early as
7-day post-injection and lasted for at least 5 weeks. Importantly, mTOR knockdown occurred in large (NF200) and small-
diameter neurons (nociceptors). The viral administration induced an increase of Iba1 immunoreactivity in the DRGs, which
was likely attributed to the expression of GFP but not siRNA. Rats with mTOR knockdown in DRG neurons showed normal
general behavior and unaltered responses to noxious stimuli. In conclusion, intrathecal AAV5 is a highly efficient vehicle to
deliver siRNA and generate gene knockdown in DRG neurons. This will be valuable for both basic research and clinic
intervention of diseases involving primary sensory neurons.
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Introduction
Dorsal root ganglia (DRG) harbor the cell bodies of primary
sensory neurons, which send afferent axons and convey sensory
information from the periphery to the spinal cord. Abnormal gene
expression in primary sensory neurons is implicated in the
hyperpathia following nerve and tissue injury. Thus, in chronic
pain conditions, a drastic change in the expression of a variety of
DRG genes has been noted, including increased expression of
sodium channels [1] and the a2d1 subunit of voltage-gated
calcium channels [2–3], which are thought to contribute to the
hyperexcitability of DRG neurons and the associated hyperalgesia
and allodynia. In addition, receptors to cytokines, chemokines and
growth factors such as TNF, bradykinin, NGF and catecholamines
are increased following nerve injury [4–7]. Antagonizing these
injury-induced gene changes in DRG neurons can prevent trophic
changes and alleviate facilitated pain states. Thus, selective gene
knockdown in DRG neurons can be achieved by intrathecal (IT)
application of antisense oligodeoxynucleotides (oligos) or siRNAs.
Although antisense oligos directed against some pro-nociceptive
molecules in DRG (e.g. Nav1.3, Nav1.8) displayed analgesia [8–
9], the utility of antisense oligos and synthetic siRNA are limited
by several factors including toxicity and short-lasting effect [10].
Alternatively, siRNA can be derived from a short hairpin
precursor that is expressed from a viral vector [11]. Recently it has
been reported that several serotypes of adeno-associated virus
(AAV) are efficient in transducing DRG neurons in rodents [12–
18]. However, the transduction efficiency and tropism in the DRG
vary considerably, depending upon the routes of administration,
animal species and viral serotypes. AAV5 vectors directly injected
into rat DRGs resulted in transduction in up to 90% of the
neurons, including most nociceptors [13]. In contrast, following IT
injection in mouse, the same serotype targeted large-diameter
DRG neurons, while excluding the isolectin-B4 (IB4)–binding,
non-peptidergic nociceptors [12]. AAV6 transduces both neurons
and satellite cells in rats following direct DRG injection [13] but
preferentially transduces neurons following mouse sciatic nerve or
IT injection [14]. Understanding the vector tropisms is important
for studies aiming to target certain subsets of DRG neurons.
The in vivo efficacy of AAV-mediated RNA interference in the
nervous system in general has been extensively studied but
information regarding the DRG is still limited. A recent paper
reported that AAV5 encoding a short-hairpin RNA produced a
significant loss of neuropilin2 mRNA in the rat DRG following a
direct injection [19]. While the result is interesting, neuropilin2 is
not expressed in all DRG neuron populations. It is therefore
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32581difficult to determine the cell types that can be targeted by AAV-
encoded siRNA. Further, direct injection of DRG requires an
invasive surgical procedure that is time-consuming and may itself
cause inflammation and pain. Intrathecal administration as a less
invasive approach produces satisfactory viral transduction but the
capacity of IT vector to deliver siRNA has not been evaluated. In
the current study, we aimed to investigate: 1) the transduction
efficacy and tropism of an AAV5 vector in rat DRG and spinal
cord after an intrathecal delivery, and 2) the efficiency of gene
expression knockdown in rat DRG by an siRNA when delivered
by the AAV5 vector. We choose mTOR as the target gene, for its
ubiquitous expression in DRG neurons and for its reported role in
peripheral nociception [20].
Results
GFP expression in the DRG and spinal cord following
intrathecal AAV5 administration
To study the transduction efficacy and tropism of AAV5 in rats,
we first constructed a vector encoding GFP driven by a
cytomegalovirus (CMV) promoter. Ten microliters of virus (10
11
viral particles) was administered in adult rats through an
intrathecal catheter, with the tip ending at the spinal level of
L3–L4. The GFP expression began to be visualized in the DRG
and spinal cord at 1 week following the vector administration,
however the intensity of GFP immunoreactivity at this time point
was very weak (not shown), and the distribution pattern was not
analyzed. A profound GFP expression was observed after 2 weeks
in the lumbar DRG neurons (Figure 1a), while in the thoracic and
cervical DRGs GFP was not detectable (figure 1b and c). We have
analyzed a total of 3781 neurons in the L4, L5 and L6 DRGs from
three rats, 44% (1672) of those neurons were GFP-positive.
Interestingly, the GFP-labeled neurons were predominantly of
large to medium size (figure 1d). Out of all the GFP-positive
profiles in the DRG, 38% were large (.1200 mm
2), 41% were
medium (.600 mm
2and ,1200 mm
2) and only 21% were small
(,600 mm
2). Conversely, out of all the neuronal profiles, GFP was
observed in 100%, 52% and 20% in large, medium and small
profiles respectively. Double immunofluorescence study revealed
that over 80% of the GFP-positive neurons were co-labeled with
NF200, a marker for myelinated fibers (figure 2a and e). A small
portion of transduced neurons are co-labeled with nociceptor
markers such as TRPV1, CGRP and IB4 (figure 2b–e).
In the spinal cord, GFP was detected in abundance at the
lumbar level (figure 3a), and to a much less degree at the thoracic
or cervical level (figure 3b and c). The spinal GFP immunoreac-
tivity was mostly present in the deeper dorsal horn, dorsal columns
and nerve roots attached. GFP was also observed in the ventral
horn and white matter, although the labeling intensity was much
lower (figure 3a–c). In the dorsal horn, the fibrous pattern and
minimal co-labeling with spinal cord neuN (figure 3d) suggested
the major source of GFP was primary afferents. There was a
preferential co-labeling of GFP with NF200 but not IB4 or CGRP
in the spinal cord dorsal horn (figure S1). In addition, GFP was
observed in the sciatic nerves and the nerve terminals in the
plantar skin of the hind paw (figure S2).
AAV5-mediated knockdown of mTOR expression
A similar preference for large-diameter DRG neurons by AAV8
and AAV9 was observed in our pilot study, while the transduction
efficacy of AAV5 was evidently the most consistent and
outstanding among the three AAVs. We therefore selected
AAV5 in the following siRNA studies. Two siRNAs targeting
mTOR (si-TOR and si-TOR’) and one control siRNA targeting
luciferase (si-Luc) were constructed as short-hairpin RNAs
downstream of a U6 promoter (figure 4a). The vectors also
encoded a GFP gene driven by a phosphoglycerate kinase (PGK)
promoter. GFP-alone vector or si-Luc vector treatment did not
alter the mTOR level in the lumbar DRGs, compared to the naı ¨ve
control (figure 4b and c). However, a significant reduction of
mTOR was observed in the lumbar DRG homogenates in rats
treated with either of the mTOR siRNA vectors at two week
following the IT administration (figure 4d and e). The two vectors
exhibited similar potency and induced a comparable degree of
mTOR knockdown (figure 4dand e, a reduction of 88% for si-
TOR and 76% for si-TOR’, compared to si-Luc). Confocal
immunohistochemistry revealed that the pattern of GFP expres-
sion driven by the PGK promoter is similar to that driven by the
CMV promoter (the siRNA-less vector). Strong GFP expression is
predominantly present in large to medium-diameter neurons and
preferentially co-localized with NF200 (figure S3). mTOR labeling
is intact in rats treated with the control si-Luc vector and present
in most if not all neurons (fig. 4f). As a result, extensive co-labeling
of mTOR and GFP was observed. The level of mTOR was greatly
reduced in DRG neurons from rats received si-TOR or si-TOR’
vectors and the co-labeling of mTOR with GFP was profoundly
reduced (fig. 4g and h). The down-regulation of mTOR is not
observed in the lumbar spinal cord or DRGs from thoracic or
cervical levels (figure S4).
Interestingly but unexpectedly, the knockdown of mTOR was
not confined to GFP-positive neurons (figure 4g and h). A
significant portion of nociceptors (i.e. small diameter, type B
ganglion neurons), which did not express detectable GFP, also
exhibited reduced mTOR labeling after the si-TOR treatment
(figure 5a and b). This prompted us to further examine the time
course of mTOR knockdown in a correlation with the expression
of GFP. We found that unlike GFP, which was detectable
Figure 1. Expression of GFP and NeuN in rat DRG following
intrathecal vector injection. A,B and C) GFP (green) and NeuN (red)
were co-labeled in A) lumbar, B) thoracic and C) cervical DRG at 2 week-
post vector injection. D) Bar graph represents size distribution of DRG
neurons with and without GFP labeling. A total of 3781 neurons from
the L4, L5 and L6 DRGs of 3 animals were included. Scale bar, 250 mm.
doi:10.1371/journal.pone.0032581.g001
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regulation of mTOR became apparent as early as 1 week
(figure 5c). At this time point, GFP expression was significantly
lower. This observation provides important information suggesting
that though the efficacy of viral transduction is often evaluated by
GFP expression, it may underestimate the RNA interference
effects. The siRNA-mediated knockdown lasted for at least 5
weeks, the longest time period examined in this study (figure 5c).
Cytotoxicity and behavior consequences following the
mTOR expression knockdown
We next assessed the cytotoxicity of the intrathecally adminis-
tered AAV5 siRNA vectors. In the lumbar DRG where most of
the transduction occurred, neurons appeared healthy judged by
NeuN immunolabeling (figure 4f–h). We did not observe any
expression of ATF3, a marker for neuronal injury (figure 6a), even
in neurons with intense GFP expression. There was no visible
myelin damage in the sciatic nerves (figure 6b). We did, however,
notice an increase of Iba1 immunoreactivity in the lumbar DRGs
(figure 6c), which could indicate the activation of microglia or
invasion of macrophages. There was a similar degree of Iba1
increase after the three siRNA vectors or the siRNA-less vector
(CMV-GFP), suggesting this phenomenon was unlikely due to
mTOR knockdown or the expression of vector-derived small
RNAs. The Iba1 expression in the cervical DRG (figure 6c) or the
spinal cord (data not shown) was not elevated.
We further assessed the changes in pain behaviors following the
mTOR knockdown in the lumbar DRGs. Rats treated with the
Figure 2. Expression of GFP in different populations of neurons in the lumbar DRG. A,B C and D) GFP (green) was co-labeled with A)
NF200, B) TRPV1, C) CGRP and D) IB4 (red) at two week following vector administration. Arrowheads indicate co-localization of GFP with the
respective cell marker. E) Bar graph represents percentage of GFP-positive neurons co-labeled with the aforementioned markers. The data are
presented as mean 6 SEM of 3 rats. Scale bar, 100 mm.
doi:10.1371/journal.pone.0032581.g002
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animals that were catheterized but did not receive an AAV vector
(figure 7a). Compared to the naı ¨ve rats or GFP vector treated rats,
si-Luc and si-TOR group had comparable baseline thermal and
tactile pain thresholds (figure 7b and c). Rats developed similar
degree of flinching behavior in the formalin model (figure 7d) and
allodynia in the spinal nerve ligation neuropathic pain model
(figure 7e) in the si-Luc and si-TOR groups.
Figure 3. Expression of GFP in the spinal cord following intrathecal vector injection. A,B and C) GFP (green) expression in A) lumbar,
B) cervical and C) thoracic spinal cord at 2 week-post intrathecal vector injection. D) Co-labeling of GFP (green) and NeuN (red) in the lumbar spinal
cord dorsal horn. Scale bars, A–C, 1000 mm; D, 250 um.
doi:10.1371/journal.pone.0032581.g003
Figure 4. Expression of mTOR in lumbar DRGs following intrathecal vector injection. A) Schematic drawing of the AAV vector that
encodes sh-RNA. The sequences of the two active and one control siRNA (si-Luc) are shown. B) Representative Western blots showing levels of mTOR
and beta-tubulin in naı ¨ve rats or at two week following vector administration in the lumbar DRGs (L4 and L5 DRGs from both sides were pooled).
C) Histogram represents the mean mTOR levels in respect to the naive group. The data are presented as mean 6 SEM of 4–6 rats per group.
D) Representative Western blots showing levels of mTOR and beta-tubulin at five week following vector administration in the lumbar DRGs (L4 and L5
DRGs from both sides were pooled). E) Histogram represents the mean mTOR levels in respect to the control group (si-Luc). The data are presented as
mean 6 SEM of 4 rats per group. F, G and H) Confocal images of mTOR (red), GFP (green) and NeuN (blue) in L5 DRG at two week following F) si-Luc,
G) si-TOR and H) si-TOR’ vector administration. Scale bar, 100 mm. PGK, phosphoglycerate kinase promoter; ITR, inverted terminal repeat; U6, U6
promoter.
doi:10.1371/journal.pone.0032581.g004
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Gene silencing in the primary sensory neurons is desirable for
basic research such as neuronal development, nerve regeneration
and mechanisms of pain, and, now, for development of potential
therapeutics. Gene expression knockdown in DRG neurons can be
achieved by intrathecal (IT) delivery of synthetic siRNA or
antisense oligodeoxynucleotides. However, the knockdown is
usually transient and often associated with toxicity. In the current
study, we characterized an alternative approach, AAV-encoded
siRNA, to produce inhibition of gene expression in DRG neurons.
We demonstrated that AAV5, when injected intrathecally, was
highly efficient in transducing DRG neurons and establishing gene
expression knockdown. We further demonstrated that the
knockdown targeted all neuron populations and was associated
with minimal cytotoxicity.
The transduction rate of AAV5 in DRG neurons was estimated
to be 50% using GFP as a marker. AAV5 appeared to favor
NF200-positive, large to medium-diameter DRG neurons in our
study. Importantly, the nociceptors, especially the IB4-positive
population, were found to express low level or no GFP. This
transduction profile is similar to a study using mice, where AAV5
was administered intrathecally by lumbar puncture [12], though in
the case of direct injection of AAV5 to DRG there was GFP
expression in nociceptors including IB4-positive, non-peptidergic
neurons [13].
In the spinal cord sections, GFP was mainly detected in the
dorsal column, deep dorsal horn and dorsal roots. This
distribution was consistent with the prominent GFP labeling in
the NF200-positive DRG neurons, which give rise to large-
diameter, myelinated primary afferents and the transport to the
distal terminals. The lack of GFP labeling in the superficial layers
paralleled the very modest expression of GFP in nociceptors.
Importantly, there was almost no cell body labeling in the dorsal
horn, suggesting that AAV5 vector either does not penetrate well
into the gray matter or was not taken up by non-afferent neurons.
It has been hypothesized that the viral vector may enter the DRG
neurons through dorsal roots, which are accessible to intrathecally
administered agents [10].
In some rats, we did observe lower intensity GFP labeling in the
ventral horn and white matter. Similar to dorsal horn labeling,
ventral horn GFP was predominantly associated with nerve fibers.
Occasionally we could see ventral horn cell bodies, presumably
motor neurons labeled with GFP in the sacral region. The GFP
labeling in the white matter was almost invariably associated with
GFAP (not shown), suggesting it was of astrocyte origin.
AAV5 was chosen over other serotypes (AAV2, 6, 8 and 9) for
superior transduction efficacy in the DRG as evidenced by GFP
expression, a finding consistent with a previous report [13]. In our
preliminary study, IT AAV2 and 6 produced no detectable GFP
expression, neither in the DRG nor in spinal cord, although a
previous study reported superb transduction in mouse DRG by IT
AAV6 [14]. AAV8 and AAV9 produced substantial amount of
GFP in some DRG neurons however the diffusion was limited
compared to AAV5. We think low dose was a possible reason to
explain why those vectors were outperformed by AAV5 in our
preliminary study. Interestingly, different AAV serotypes seem to
target different populations of neurons even with the same route of
delivery. Intrathecal AAV6 preferentially transduced nociceptors
[14] while AAV9 produced considerable labeling in motor
neurons [21–22]. The mechanism behind these preferences
remains to be deciphered.
An important observation was that GFP expression was largely
confined to the lumbar area. Few cells from the cervical and
thoracic DRGs were labeled with detectable GFP. Indeed, there
was no GFP expression in the cervical or thoracic dorsal horn. The
weak GFP expression that was restricted to the dorsal column
likely comes from the proprioceptive primary afferent neurons at
the lumbar level. This spatial localization of viral transduction
reflects the lack of prominent cerebrospinal fluid (CSF) movement
Figure 5. Expression of mTOR in L5 DRG following intrathecal vector administration. A) Confocal images of mTOR (red) co-labeled with
NF200, CGRP, TRPV1 or IB4 (green) in L5 DRG 2 weeks following the si-Luc or si-TOR vector injection. Double labeled neurons are indicated with
asterisks. B) Bar graph represents percentage of mTOR-positive neurons co-labeled with the aforementioned markers. The data are presented as
mean 6 SEM of 3–4 rats except TRPV1 represents a single rat. C) GFP (green) and mTOR (red) in L5 DRG at 1 week following the si-Luc vector and 1, 2
and 5 weeks following the si-TOR vector injection. Scale bars, A, 50 mm and C, 100 mm.
doi:10.1371/journal.pone.0032581.g005
Figure 6. DRG ATF3, Iba1 immunohistochemistry and sciatic nerve myelin staining following intrathecal vector injection.
A) Expression of ATF3 in the L5 DRGs in rats treated with spinal nerve ligation (SNL, 2 weeks), si-Luc or si-TOR AAV5 vectors (4 weeks). B) Myelin
staining of the sciatic nerve from rats treated with si-Luc, si-TOR or si-TOR’ vectors (4 weeks). C) Expression of IbaI in the L5 DRGs in a naı ¨ve rat or rats
received si-Luc, si-TOR or GFP-only vectors. A cervical DRG from a rat treated with si-TOR vector was also shown. Scale bar, 100 mm.
doi:10.1371/journal.pone.0032581.g006
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that the circulation of the CSF is limited and the diffusion of large
particles (e.g. AAV) in the CSF is relatively slow [23–24]. The
spatially limited transduction is of particular advantage where
targeting of only the lumbar DRGs is desired. The spatial
confinement of transduction, as is the distribution of most
intrathecally delivered agents, can be manipulated by changing
the positioning of the catheter tip and the volume of viral vector
dosing. Smaller volumes would likely be useful under these
circumstances for targeting of a yet fewer number of DRGs. For
transduction of a specific ganglion, a direct injection may be more
appropriate, but that brings out the issue regarding the likelihood
of injury.
mTOR is distributed in all populations of DRG neurons [25],
where it has been implicated in peripheral nociception [20]. In the
present study, we used AAV5-encoded shRNA to generate a
knockdown of mTOR gene expression that was confined to DRG
neurons. The gene knockdown was selective, long-lasting and
segmentally localized (only observed in the lumbar DRGs). At 5
weeks following the vector administration, the mTOR protein was
reduced to 20% of the control level. To our surprise, mTOR
silencing was observed in many more cells than what would have
been predicted from the GFP distribution. Significant mTOR
reduction was not only observed in large to medium-diameter
neurons, but also in various groups of nociceptors, including IB4-
positive nociceptors, which displayed no detectable GFP. This
observation indicates AAV5 was able to transduce most if not all
groups of DRG neurons. However, the low expression level of
GFP in some neuron populations (i.e. nociceptors) might have lead
to an underestimation of the vector transduction rate. A number of
factors could contribute to the expression disparity of GFP. Higher
level of GFP expression in large-diameter neurons may result from
higher copies of viral genomes present in the cell, subsequently
higher rate of transcription and translation. It was reported that
the level of GFP mRNA peaked after 1 week following a direct
injection of AAV5 into the DRG, while the level of GFP protein
kept increasing throughout a 12-week period [13]. It is possible
that, within the time frame of our experiment (5 weeks), GFP
might not have reached detectable level in nociceptors. For more
accurate assessment of viral transduction, other means such as in
situ hybridization shall be considered.
In previous reports, vector shRNA-mediated knockdown and
the expression of a reporter gene (e.g. GFP) usually correlate well
in their spatial distribution [26–27]. However, current results
suggest that they should be treated as two separate events which do
not necessarily parallel each other. The required level of siRNA to
induce RNA interference is likely different from that of GFP
mRNA to mediate detectable GFP expression. Moreover, the
siRNA was presumably transcribed by RNA polymerase III,
which recognizes the U6 promoter. The transcription of GFP
mRNA was driven by an RNA polymerase II promoter. It is
conceivable that the two types of RNA polymerases work
independently and the siRNA and mRNA were produced at
different rates. These hypotheses may be addressed in future
experiments.
Self-complementary (sc) AAV vectors bypass the rate-limiting
step of second-strand synthesis. This type of AAV is known to
mediate faster onset of transgene expression [28–29]. GFP was
detected in retinal pigment epithelium as early as day 1 following
trans-cornea sub-retinal injection of a sc-AAV5 vector [30].
Although we did not evaluate GFP expression or mTOR
knockdown at such an early stage, we found that at 1 week
Figure 7. Weight gain and nociceptive behaviors following the siRNA vectors. A) Daily weight gain of rats after receiving no vector
(control), si-Luc or si-TOR vector. The mean weight gain in a two week period following vector injection is shown. B) Thermal and C) mechanical
thresholds for naı ¨ve rats and rats treated with GFP, si-Luc or si-TOR vector for two weeks. D) Total number of flinches in phase I (1–9 min) and II (10–
60 min) following intraplantar formalin (2.5%, 50 mL) injection. Rats received si-Luc or si-TOR vector two weeks before the formalin tests.
E) Mechanical thresholds of the ipsilateral paw following unilateral L5 and L6 spinal nerve ligation. Rats received si-Luc or si-TOR vector two weeks
before the SNL surgery. The data are presented as mean 6 SEM of 6–8 rats per group.
doi:10.1371/journal.pone.0032581.g007
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tion in the target tissues. The results indicate IT AAV-mediate
RNAi effects are well within a time frame that is suitable for
clinical intervention of diseases.
mTOR is reportedly involved in many cellular processes,
notably cell replication and differentiation. mTOR inhibitors are
currently under development for potential anti-cancer drugs. It is
apparent that knocking down mTOR has little effects on the
survival of primary sensory neurons, possibly due to the fact that
these neurons are terminally differentiated. Transduced DRG
neurons exhibited normal, healthy morphology which was
comparable to naı ¨ve tissues, regardless of the level of mTOR
expression. No signs of neuronal damage such as ATF3 induction
or myelin loss have been observed. The data also argue for a lack
of toxicity from vector-derived siRNA in DRG neurons, which is
consistent with a recent report [19]. An AAV5 vector encoding a
siRNA was directly injected into the DRG and no detectable
cytotoxicity was reported.
An increase in DRG Iba1 immunoreactivity was the only sign of
vector-induced adverse side-effects that we could detect. In many
cases, increased Iba1 is viewed as an indicator for microglia/
macrophage activation. It is unlikely that the glia activation was
directly related to the vector-mediated RNAi effects, because a
comparable degree of Iba1 upregulation was observed following
an ‘‘RNA-less’’ AAV5 vector that encodes GFP only. There is,
however, a possibility that the increased Iba1 is attributable to
GFP, or alternatively to the viral capsid. To note, the Iba1 increase
was present only in the lumbar DRGs. In thoracic or cervical
DRGs, where viral transduction was negative, there was no Iba1
increase. It would be interesting to investigate in future studies if a
‘‘GFP-less’’ AAV5 vector or other serotypes elicit the same
reaction. Despite the apparent Iba1 increase in the lumbar DRGs,
AAV5-treated rats displayed overall good health, normal weight
gain and no detectable signs of stress. Baseline pain thresholds, a
sensitive measure of function, were unaltered suggesting no
abnormities.
mTOR has been implicated in nociceptive signal transmission,
both at peripheral sites and spinal dorsal horn [20,31–34]. A
previous study [20] showed that peripheral inhibition of mTOR
by intraplantar rapamycin decreases the thermal sensitivity of a
subset of A-nociceptors in non-injured rats, and local rapamycin
treatment attenuated mechanical hypersensitivity in the spared
nerve injury (SNI) neuropathic pain model. However, we did not
observe any changes on pain thresholds in rats with DRG mTOR
knockdown, neither in the acute thermal or mechanical tests nor
the two chronic pain models. A significant reduction of mTOR
protein in lumbar DRGs was confirmed by both Western blotting
and immunohistochemistry. We also observed a decrease of
phospho-S6 protein (data not shown), suggestive of an inhibition of
mTOR enzymatic activity, in the treated lumbar DRGs. It is
known that in addition to DRG, mTOR is expressed extensively in
spinal dorsal horn neurons including the NK1 projection neurons
which are essential in pain signal transduction (Xu et al 2011).
Since mTOR expression in spinal cord is intact in the AAV-
treated animals (see figure S4), given the observed spinal
pharmacology of mTOR, we suggest that mTOR function in
primary sensory neurons (as knocked out selectively with IT–
AAV5) is not essential for nociception. It should be noted that
other signaling pathways, such as mitogen-activated protein kinase
(MAPK) pathways exist in the primary sensory neurons that may
also play important roles. These alternative pathways may have
undergone adaptive changes to compensate for a chronic
knockdown of mTOR and a normal pain behavior was preserved.
It is interesting to note that IT antisense oligo knockdown of a p38
MAPK isoform (p38-b) indeed diminished the hyperalgesic pain
state [35]. Those studies do not permit assessment of whether the
relevant site of p38 knock down was spinal or DRG. Further
experiments could indeed assess the role of DRG-p38-b by IT-
AAV5-mediated transduction.
In conclusion, the current study showed that intrathecal
administration of AAV5 is a highly efficient and reliable paradigm
for delivering small RNAs and generating gene knockdowns in the
primary afferent neurons. The majority populations of DRG
neurons were targeted by the RNAi effect, regardless of the
expression level of a reporter gene, GFP. Intrathecal AAV5 shall
be exploited further for the studies and treatments of diseases
affecting DRG neurons. Further development of this approach will
require assessment of the distribution properties in large animal
model (e.g. dog) [36–37] to define safety and efficacy.
Materials and Methods
Ethics Statement
All experiment protocols (S00148R) were approved by the
University of California, San Diego, Institutional Animal Care and
Use Committee in accordance with the Guide for the Care and
Use of Laboratory Animals (National Institutes of Health
publication 85–23, Bethesda, MD, USA).
Animals
Male Sprague–Dawley rats (200–250 g; Harlan, Indianapolis,
IN, USA) were housed in a light-controlled room (light from
07:00–19:00 h) with free access to food and water. Surgical
procedures and testing occurred during the light cycle. Measures
were taken to minimize the pain and discomfort of the
experimental animals.
Construction and preparation of viral vectors
siRNA targeting the rat mTOR mRNA (NM_019906) were
selected by the ‘siRNA design program’ (http://jura.wi.mit.edu/
siRNAext/) from the Whitehead Institute for Biomedical Research
[38]. A spacer (TTCAAGAGA) was inserted into the antisense
and sense sequences to generate a ‘‘stem-loop’’ structure [11].
DNA oligomers were synthesized according to the ‘‘stem-loop’’
sequences (Integrated DNA Technologies, Coralville, Iowa),
annealed and cloned into an AAV plasmid. The oligomers were
placed downstream of a U6 promoter and the insertion was
confirmed by sequencing. The same AAV plasmid also encoded
green fluorescent protein driven by a phosphoglycerate kinase
promoter.
To produce self-complementary double-strand DNA genome
AAV vectors (scAAVs), a 20 base pair sequence was deleted in the
terminal resolution site (TRS) in one of the two ITRs in the pAAV
plasmid [29,39]. Helper virus-free scAAV5 vectors were produced
by transient transfection of HEK293T cells with the vector
plasmid, pRep2-Cap5 and pAd-Helper plasmid [40]. Plasmid
pRep2-Cap5 was constructed at the UCSD Vector Core by sub-
cloning of the Cap gene from pXYZ5 (obtained from Dr. Snyder,
U. Florida [41]). Cell lysates prepared at 72 hr after transfection
were treated with benzonase and viruses were pelleted through
25% sucrose-cushion ultracentrifugation. The pellets were resus-
pended and the viruses were further purified through anion-
exchange column chromatography (Q-Sepharose, GE Health
Science) followed by concentration through 25% sucrose-cushion
ultracentrifugation. The final pellets were resuspended with a
solution consisting of 10 mM Tris-HCl, pH7.9, 1 mM MgCl2 and
3% sucrose. Virus titers were determined by measuring the
genome copies by real-time Q-PCR.
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The implantation of intrathecal catheter in rats has been
previously described [42–43]. AAV5 vectors were prepared to a
concentration of 1610
13 viral particles/mL. Vectors were
delivered in 10 mL followed by 10 mL of saline through the
intrathecal catheter 24 hr following the implantation. Catheters
were removed 72 hr following the vector injection.
Western blotting (WB)
Five weeks following the vector injection, rats were deeply
anesthetized by isoflurane and decapitated. Lumbar spinal cord
dorsal quadrants and DRGs from the L4 and L5 levels were
harvested in extraction buffer [50 mM Tris buffer, pH 7.4,
containing 0.5% Triton X-100, 150 mM NaCl, 1 mM EDTA,
3% SDS, protease inhibitor cocktail (1:100, P8340, Sigma) and
phosphatase inhibitor cocktail I and II (1:100, P2850 and P5726,
Sigma)]. Samples were sonicated, centrifuged at 14,500 rpm for
15 min and the supernatants were subject to sodium dodecyl
sulfate polyacrylamide gel electrophoresis (4–12% Bis-Tris gel,
Invitrogen, Carlsbad, CA, USA). Samples were transferred to
nitrocellulose membranes and incubated with the primary
antibody (mTOR, 1:1000, Cat. No. 2972, 1:1000, Cell Signaling
Technology, Danvers, MA) overnight at 4uC. After washing,
membranes were probed with appropriate Horseradish Peroxidase
conjugated secondary antibody diluted at 1:10,000. Membranes
were then incubated with SuperSignal Chemiluminescent Sub-
strate reagents (Pierce, Rockford, IL, USA) and the luminescent
signal was exposed to film and developed for further scanning and
quantification. The membranes were stripped with a Re-Blot
western blot recycling kit (Chemicon, Temecula, CA, USA) and
re-probed with b-tubulin (1:50,000, Sigma, St. Louis, MO). The
optical density (OD) of immunoreactive bands was quantified
using ImageQuant software (Molecular Dynamics, Sunnyvale,
CA, USA).
Immunohistochemistry (IHC)
Animals were terminally anesthetized with Euthasol (0.5 mL,
Virbac Animal Health, Inc. Fort Worth, TX, USA) and
transcardially perfused with saline followed by 4% paraformalde-
hyde in PBS. Tissues were dissected and post-fixed in the same
fixative for 2 hr at 4uC. The tissues were then transferred to 30%
sucrose at 4uC for 72 hr. Spinal cord (30 mm), sciatic nerve
(30 mm), skin (30 mm) and DRG (10 mm) sections were cut on a
Leica cryostat (CM1800) and mounted on superfrost plus slides
(12-550-15, Fisher Scientific, Pittsburgh, PA, USA) before
proceeding to IHC. Non-specific binding was blocked by
incubation in 3% normal goat serum or 3% normal donkey
serum (vector laboratories, Malden, MA, USA) in PBS with 0.3%
Triton X-100 followed by incubation with the primary antibodies
overnight. The antibodies used were: rabbit anti-mTOR (1:500,
2972, Cell Signaling Technology, Danvers, MA), rabbit anti-GFP
(1:1000, A6455, Invitrogen, Carlsbad, CA), rabbit anti-ATF3
(1:1000, sc-188, Santa Cruz Biotechnologies; Santa Cruz, CA),
mouse anti-NeuN (1:500; MAB377, Millipore, Temecula, CA),
mouse anti-glial fibrillary acidic protein (GFAP, 1:1000, MAB360,
Millipore, Temecula, CA), rabbit anti-Iba-1 (1:1000, 019-19741,
Wako, Richmond, VA); goat anti-TRPV1 (1:500, sc-12498, Santa
Cruz Biotechnologies; Santa Cruz, CA), goat anti-CGRP (1:500,
ab36001, Abcam, Cambridge, MA), mouse anti-NF200 (1:1000,
N0142, Sigma, St. Louis, MO), Alexa647-IB4 (1:1000, I32450,
Invitrogen, Carlsbad, CA). Slides were washed in PBS and
incubated in appropriate fluorescent secondary antibodies (Invi-
trogen, Carlsbad, CA). Some tissues were counterstained with TO-
PRO-3 (1:1000, Molecular Probes). Coverslips were mounted with
ProLong antifade medium (Molecular Probes, Eugene, OR, USA).
Non-specific labeling was determined by excluding the primary
antibodies.
Confocal microscopy and quantification
Confocal images were acquired by a Leica TCS SP5 confocal
system at fixed settings using a 106or 206objective at a digital
size of 102461024 pixels. In case of multiple-labeled IHC, images
of each channel were acquired by sequential scanning. NIH Image
J was used to quantify the colocalization of different cell markers
and GFP or mTOR by a researcher who was blind to the
treatment. Cell profiles were manually encircled and the intensity
of each color channel was recorded. The threshold for positive
labeling was arbitrarily set as 2 folds of the average intensity on the
control IHC tissue (primary antibody omitted). For GFP labeling,
the threshold was determined on naı ¨ve tissue with no viral vector
injection. The images were adjusted with Adobe Photoshop
software to enhance clarity.
Myelin staining of sciatic nerves
Plastic-embedded 1 mm-thick nerve sections were used to
analyze myelin neuropathology, as previously described [44].
Anesthetized rats were perfused with 4% paraformaldehyde. The
sciatic nerves were isolated and fixed in 2.5% glutaraldehyde in
0.1 M phosphate buffer, post-fixed in 1% aqueous osmium
tetroxide, dehydrated and embedded in araldite resin. Sections
were cut with a glass knife on an automated Lieca RM2065
microtome and stained with Methylene blue Azure II for light
microscopic examination.
Behavior tests
All behavioral measurements were made by observers blinded
to the treatment groups.
Baseline thermal and mechanical threshold
Paw withdrawal latency to a thermal stimulus was measured by
a Hargreaves type device [45]. The hind paw was stimulated by a
radiant heat. A withdrawal of the paw from the heat source would
terminate the stimulus and the latency was recorded automatically.
Mechanically induced response in the hind paws was determined
by the ‘‘up-down’’ method using von Frey filaments [46].
Formalin-induced flinching behavior
Formalin-induced flinching was quantified by an automated
system [47]. A metal band was glued to the plantar surface of the
left hind paw. The dorsal surface was injected with formalin
solution (2.5% in physiological saline, 50 mL) by a 30-gauge
needle. Rats were placed into the test chamber immediately and
the number of flinches of the injected paw was counted
automatically. The data are expressed as total number of flinches
observed during phase 1 (0–9 min) and phase 2 (10–60 min).
Spinal nerve ligation
Rats were anesthetized with isoflurane and the L5 transverse
process on the left side was partially removed to expose the L5 and
L6 spinal nerve. A 6-0 silk tight ligation was made on the L5 and
L6 spinal nerve [48]. Rats were allowed to recover for three days
before behavior assessment.
Statistics
The data are presented as the mean 6 S.E.M. One-way
ANOVA followed by a Tukey post-hoc test was used when more
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when two groups were compared.
Supporting Information
Figure S1 Co-labeling of GFP (green) with IB4, CGRP or
NF200 (red) in the lumbar spinal cord at 2 week-post intrathecal
AAV5 vector injection. Scale bar, 250 mm.
(TIF)
Figure S2 Expression of GFP (green) and NF200 (red) in (A and
B) the glabrous skin of the hind paw and (C) sciatic nerves. ep,
epidermis; d, dermis. scale bars, a, 200 mm; B and C, 50 mm.
(TIF)
Figure S3 GFP (green) in lumbar DRG co-labeled with NF200
(red) and IB4 (blue) at two week following si-Luc or si-TOR vector
administration. Scale bar, 100 mm.
(TIF)
Figure S4 Expression of mTOR in the lumbar spinal cord and
cervical and thoracic DRGs. A) Representative Western blots
showing levels of mTOR and beta-tubulin in the lumbar spinal
cord dorsal horn at 5 week following vector administration. B)
Histogram represents the mean mTOR levels in respect to the
control group (si-Luc). C) Confocal images of mTOR in T12 and
C4 DRG 2 weeks following the si-TOR vector injection. Scale bar,
100 mm.
(TIF)
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